You have 0 items in your cart
Metabolic research is increasingly connecting two areas that were once commonly discussed separately: metabolic health and liver health.
Survodutide is one of the most advanced investigational compounds exploring that connection.
Previously known as BI 456906, survodutide is a long-acting dual receptor agonist being investigated in Phase 3 clinical programmes for both obesity and metabolic dysfunction-associated steatohepatitis, or MASH.
What makes the programme particularly interesting is its mechanism.
Survodutide targets both the GLP-1 and glucagon receptors, with researchers investigating whether this combination can influence whole-body metabolism while also producing effects within the liver.
What Is Survodutide?
Survodutide is an investigational peptide-based compound originally discovered through a collaboration between Zealand Pharma and Boehringer Ingelheim.
Boehringer Ingelheim is now responsible for its global clinical development.
The molecule is designed as a:
GLP-1 receptor agonist
- ●
Glucagon receptor agonist
It is therefore classified as a dual agonist.
Survodutide is long acting and has been developed for once-weekly administration within clinical trials.
Why Is the Liver Important?
The liver is one of the body’s major metabolic organs.
It plays central roles in processing nutrients, regulating glucose, handling lipids and managing energy stores.
Metabolic dysfunction can result in excessive accumulation of fat within liver cells.
This can form part of a condition now known as metabolic dysfunction-associated steatotic liver disease, or MASLD.
In some people the condition progresses to a more serious form involving inflammation and cellular injury: MASH.
Progressive fibrosis can subsequently develop.
This makes preventing or reducing liver damage a major area of metabolic research.
What Is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis.
The terminology has changed in recent years.
Researchers previously commonly used the term NASH — non-alcoholic steatohepatitis.
Older scientific papers and searches may therefore still refer to NASH, while current research increasingly uses MASH.
The condition involves several interconnected processes, including:
- accumulation of liver fat
- inflammation
- liver-cell injury
- metabolic dysfunction
- development of fibrosis in more advanced disease
Because these processes are interconnected, researchers are investigating compounds capable of influencing more than one aspect of the disease.
Why Combine GLP-1 and Glucagon?
GLP-1 and glucagon have different physiological roles.
GLP-1 receptor signalling has been extensively investigated in relation to glucose regulation, appetite-related signalling and other metabolic processes.
Glucagon signalling has traditionally been associated particularly with regulation of hepatic glucose production.
But glucagon biology is considerably broader.
Researchers have also investigated its relationship with energy expenditure, lipid metabolism and liver physiology.
Combining the two pathways therefore creates an interesting scientific hypothesis.
Could GLP-1-related metabolic effects be combined with glucagon-related activity within the liver?
Survodutide is one of the major clinical programmes attempting to answer that question.
Survodutide Was Deliberately Designed With a Receptor Bias
Dual agonists don’t necessarily activate both receptors equally.
Survodutide was engineered with substantially greater relative activity toward the GLP-1 receptor than the glucagon receptor.
This illustrates an important concept in modern peptide engineering.
Researchers aren’t simply choosing which receptors to include.
They can also attempt to control the relative strength of activity at those receptors.
This receptor balance can influence how an experimental molecule behaves.
As multi-receptor compounds become increasingly sophisticated, this is likely to become an increasingly important part of understanding their pharmacology.
What Did Earlier Obesity Research Find?
Phase 2 research investigated survodutide in adults living with overweight or obesity.
The randomised study examined different doses over 46 weeks.
Researchers reported dose-dependent changes in body weight, with the highest studied dose associated with average reductions approaching 19% among participants completing treatment at that dose.
Gastrointestinal adverse events were among the commonly reported side effects.
These results supported progression into the much larger Phase 3 SYNCHRONIZE programme.
What Is the SYNCHRONIZE Programme?
SYNCHRONIZE is the Phase 3 clinical programme investigating survodutide in obesity.
Different studies examine different populations.
These include people with overweight or obesity both with and without type 2 diabetes.
A cardiovascular outcomes study is also part of the programme.
This allows researchers to examine considerably more than changes in body weight alone.
Large Phase 3 programmes are designed to provide broader information regarding efficacy, safety and outcomes across more diverse populations.
Survodutide and MASH Research
The liver programme is what makes survodutide particularly distinctive.
Phase 2 research investigated the compound in people with MASH and liver fibrosis.
Researchers assessed liver histology — microscopic examination of liver tissue — rather than relying exclusively on changes in body weight or blood markers.
The findings supported progression into Phase 3 development.
Survodutide is now being investigated in the LIVERAGE clinical programme.
What Is the LIVERAGE Programme?
LIVERAGE examines survodutide in people with MASH and fibrosis.
Another study, LIVERAGE-Cirrhosis, investigates people whose disease has progressed to compensated MASH-related cirrhosis.
These studies address an important question:
Can modifying metabolic signalling influence the actual progression of liver disease?
That’s a substantially different scientific objective from simply measuring short-term metabolic changes.
Why Fibrosis Is So Important
Fibrosis is the accumulation of excessive scar-like tissue following repeated or chronic tissue injury.
Within the liver, progressive fibrosis can interfere with normal structure and function.
Advanced fibrosis can eventually progress to cirrhosis.
Researchers studying MASH therefore pay close attention to whether experimental compounds can influence fibrosis as well as inflammation and liver fat.
This requires carefully designed, long-duration studies.
Survodutide Has Received Regulatory Research Designations
Survodutide remains investigational, but its MASH programme has received significant regulatory recognition.
The US Food and Drug Administration granted Breakthrough Therapy designation for investigation in adults with non-cirrhotic MASH and moderate or advanced fibrosis.
The European Medicines Agency has also included the programme within its PRIME scheme.
These designations don’t mean the compound is approved.
They are mechanisms intended to support development of medicines being investigated for serious conditions where preliminary evidence suggests potential to address an unmet need.
Why Survodutide Is Scientifically Interesting
Survodutide represents a broader development in metabolic research.
Researchers are increasingly looking beyond individual measurements such as body weight or blood glucose.
Instead, they’re studying how metabolic signalling influences interconnected organs and diseases.
The liver is central to that story.
Metabolic dysfunction can affect the liver, cardiovascular system, kidneys and other tissues simultaneously.
A compound being investigated across both obesity and progressive metabolic liver disease therefore provides researchers with an opportunity to study these relationships more directly.
From Metabolic Compounds to Metabolic Systems
Perhaps the most important lesson from survodutide research is that modern metabolic science is becoming increasingly system-wide.
Scientists aren’t simply asking whether a receptor can influence one measurement.
They’re asking how altering a signalling pathway affects:
energy regulation
glucose metabolism
lipid metabolism
liver biology
cardiovascular risk
and ultimately longer-term disease outcomes.
Survodutide’s Phase 3 programmes should provide considerably more information about whether GLP-1/glucagon dual agonism can meaningfully influence several parts of this interconnected metabolic system.
That makes survodutide particularly interesting not simply as another dual agonist, but as part of the expanding connection between metabolic research and liver research.
Research Notice: Survodutide (BI 456906) remains investigational and has not been approved for marketing by regulatory authorities. This article is provided for scientific and educational purposes only and does not provide medical advice, treatment recommendations or dosing guidance.